Study of Harmine in Healthy Subjects

Open-label phase I dose-escalation study in healthy adults using the continual reassessment method to identify the maximum tolerated dose of harmine; single oral dose per subject.

Seven potential dose levels (100–1200 mg) are evaluated with continuous medical monitoring on the treatment day; adverse events and dose-limiting toxicities inform subsequent dosing decisions.